Bifidobacterium bifidum (B. bifidum) usually represent the most abundant bacteria in the human intestinal flora of healthy breast-fed infants. It shows significant physiological and genetic characteristics, including adhesion to the epithelium and the metabolism of host-derived glycans. Taking advantage of the specific adaptability of B. bifidum to human intestines and its significance in supporting host health, Creative Biolabs launched the drug discovery service for probiotics B. bifidum.
B. bifidum is a bacterial species of the genus Bifidobacterium, family Bifidobacteriaceae, which belongs to the Actinobacteria phylum. It is a Gram-positive microorganism with high G+C DNA content. Like other Bifidobacterium strains, B. bifidum is anaerobic, which means it doesn't need oxygen to survive. It can neither move nor form spores. It is one of the most common probiotics in mammals, including humans. Most of B. bifidum are found in our colon, lower part of the small intestine, breast milk, and vagina.
Fig.1 Schematic representation of the main properties exerted by B. bifidum in the human gut. (Turroni, 2019)
The biological function and industrial application potential of B. bifidum have been characterized and confirmed in vivo and in vitro. The bacteria play a wide range of beneficial roles in the gut, such as maintaining a balance between good and bad bacteria, supporting the immune system, and aiding in digestion. It shows great potential in the treatment of gastrointestinal and digestive diseases, including:
B. bifidum is the second most significant species in breast-fed infants and is considered to be the predominant species in the gut flora of healthy breastfed infants. The unique ecological characteristics of it have attracted the interest of microbiologists. Currently, multiple experiments have been conducted in clinical and preclinical studies and demonstrated significant health benefits (e.g., inflammatory bowel disease (IBD), ulcerative colitis (UC), pouchitis, diarrhea, and pathogen infection).
CeD is an immune-mediated bowel disease that is unique in its known specific trigger factor: gluten. The current mainstream treatment is gluten-free diet (GFD). As new therapies developed, complementary strategies are also being studied, such as regulating the gut microbiota. Studies have shown that the number of goblet cells in the small intestine of rats with triggering factors is significantly reduced, and the intestinal barrier and tight junctions have also changed. However, when gliadin and IFN-γ were incubated with B. bifidum, the number of goblet cells increased and the production of metalloproteinases and chemokine inhibitors increased, which protected intestinal barrier, and also indicated the potential beneficial role of B. bifidum in the treatment of CeD.
To exert the potential health-promoting effect of B. bifidum in human intestines, bacteria need to reach the compartment in a feasible form, and they should also be able to persist in the intestine. Therefore, Creative Biolabs actively seize this opportunity to develop B. bifidum probiotic drug discovery services. Our R&D team fully considers the mechanism of action of bacteria, proposes personalized drug development programs based on disease states, finds the best dosage form, and provides you with the best choice.
Together with researchers and scientists around the world, Creative Biolabs is committed to providing one-stop drug discovery services for B. bifidum.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.